Key Highlights

  • ORIC Pharmaceuticals (NASDAQ:ORIC) reported a third-quarter net loss of USD 48.1 million, or USD 0.44 per share, compared with USD 32.6 million, or USD 0.33 per share, a year earlier.
  • Research and development expense rose to USD 43.4 million from USD 28.8 million, led by USD 21.2 million of external spending on rinzimetostat against USD 5.6 million.
  • Cash, cash equivalents and investments were USD 345.4 million at September 30, 2026, which management expects to fund operations into the second half of 2028.
  • Nine-month net loss reached USD 125.3 million, and the accumulated Deficit stood at USD 817.6 million, while ATM sales raised about USD 59.9 million during the nine months.

Rinzimetostat Spending Drives a Wider Quarterly Loss

ORIC Pharmaceuticals (NASDAQ:ORIC) filed its Quarterly Report on November 16, 2026. The South San Francisco company is a clinical-stage biopharmaceutical developer focused on overcoming resistance in cancer, with two lead programs: rinzimetostat, an oral PRC2 inhibitor in prostate cancer, and enozertinib, a brain-penetrant inhibitor for EGFR-mutated lung cancer. The operating loss for the quarter grew to USD 51.6 million from USD 36.7 million, and the net loss widened by USD 15.5 million to USD 48.1 million. Interest and other income of USD 3.5 million partly offset costs, down from USD 4.1 million. For nine months, the net loss was USD 125.3 million against USD 99.0 million.

Phase 3 Start and Enozertinib Data Shape the Cost Base

Research and development spending reached USD 43.4 million in the quarter, an increase of USD 14.6 million, mostly external costs for rinzimetostat. External rinzimetostat expense was USD 21.2 million, while enozertinib costs eased to USD 7.6 million from USD 9.0 million on timing of Manufacturing and clinical work. In July 2026 the company started Himalayas-1, its first global Phase 3 trial of rinzimetostat with darolutamide in metastatic castration-resistant prostate cancer, with Bayer supplying darolutamide at no cost. In October it reported enozertinib data in untreated lung cancer patients with atypical EGFR mutations, including an 84% confirmed systemic response rate and a 70% confirmed intracranial rate. General and administrative expense was USD 8.2 million, up from USD 7.9 million.

Cash Position, ATM Proceeds and the 2028 Runway

ORIC Pharmaceuticals (NASDAQ:ORIC) held USD 33.8 million in cash and equivalents, USD 227.5 million in short-term investments and USD 84.0 million in Long-Term Investments at quarter end, for the USD 345.4 million total. Operating Activities used USD 106.0 million over nine months, against USD 88.5 million a year earlier. During that period it sold 4,698,400 shares through its at-the-market program at a weighted average price of USD 12.96, raising about USD 59.9 million, and no ATM proceeds came in during the third quarter. About 103.9 million shares were outstanding on November 9, 2026, and 4,463,636 pre-funded warrants remained unexercised. In October the company also agreed that Cancer Research UK would fund development of ORIC-259, a CIP2A-targeting candidate.

Where Things Stand

The filing shows spending climbing as rinzimetostat moves into Phase 3, with the quarterly net loss up by nearly half and management still guiding to a runway into the second half of 2028. ORIC Pharmaceuticals (NASDAQ:ORIC) has no product revenue, and it states that substantial additional Capital will be needed to finish development and reach commercialization. Next markers include Himalayas-1 enrollment, the mid-2027 enozertinib data in first-line lung cancer with exon 20 insertions, and any further Equity raising beyond the existing ATM program.